Niagen NR linked to 2.5-year drop in muscle epigenetic age in Aging Cell study
A peer-reviewed analysis in Aging Cell ties Niagen Bioscience's NR supplement to a measurable reversal of muscle aging markers, signalling a shift in how the longevity industry proves its products work.
Niagen Bioscience has published a peer-reviewed analysis in the journal Aging Cell reporting that daily supplementation with its patented nicotinamide riboside (NR) was associated with a measurable reduction in the biological age of skeletal muscle. Participants who took 1,000 mg of Niagen NR over five months showed an approximately 2.5-year decrease in muscle epigenetic age acceleration, as measured by the muscle-specific MEAT clock.
The analysis drew on muscle and blood samples from three previously completed human clinical trials, supplemented by laboratory experiments in human muscle cells. Rather than relying on a single metric, researchers ran the data through seven different epigenetic clocks. Several pointed in the same direction as the MEAT clock, but not all measurements agreed.
That inconsistency matters. Epigenetic clocks capture different facets of biological aging, and no single one offers a definitive verdict. The authors and senior researcher Dr Eija Pirinen, of the University of Helsinki and the University of Oulu, stressed that additional research is needed before firm conclusions can be drawn.
The study also linked changes in mitochondrial DNA content to shifts in muscle biological age, suggesting a connection between cellular energy production and how quickly muscle tissue appears to age. Niagen Bioscience CEO Rob Fried called it "among the first human studies suggesting that Niagen NR supplementation may alter epigenetic aging in skeletal muscle, rather than simply increasing NAD+ or improving mitochondrial function."
A comparison with exercise
Researchers additionally compared the NR data with results from earlier studies of high-intensity interval training. The two interventions produced different effects depending on which clock was applied: one favoured HIIT, others favoured supplementation. The authors suggest the approaches may prove complementary, though dedicated trials testing them in combination have not yet been conducted.
Why it matters for the longevity sector
For an industry built on the promise of slowing aging, the study represents a meaningful methodological shift. The question is moving from whether a supplement can raise levels of a molecule such as NAD+ to whether it can alter the biological processes that govern tissue aging itself.
Reliable biomarkers of that kind are what investors and regulators will ultimately need before longevity therapies can move beyond niche markets. Skeletal muscle is central to mobility, metabolic health, and independence in later life, making it a particularly relevant tissue for any intervention aimed at extending healthspan.
The caveat is equally important for anyone assessing the commercial implications. This was a secondary analysis of existing trial samples, not a newly designed study. The findings are encouraging but not conclusive, and the field still lacks a consensus on how to measure biological aging in a way that satisfies both scientists and regulators.
European research institutions are embedded in this work. Dr Pirinen's dual affiliation with Helsinki and Oulu places Finnish academia at the centre of one of the sector's most active questions, and the involvement of EU-based universities lends institutional weight to results that will now face scrutiny from competitors and independent labs alike.
